FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Results & Progress
9

AOD-9604 Results — Honest Assessment

Hawk Cho·7 months ago
Giving my honest AOD-9604 results because I think this community needs more realistic reports alongside the glowing reviews. Background: 42-year-old, moderately active, primary goals were recovery and general health optimization. Positives: Sleep improved meaningfully. This was the most consistent and obvious benefit. I also noticed better recovery from workouts, though this is harder to quantify objectively. Joint comfort improved — morning stiffness that I attributed to age decreased noticeably. Neutrals: mood and energy had minor improvements that could also be attributed to better sleep. Hard to isolate causation. Negatives: cost is significant. Injection site irritation was annoying for the first few weeks. The daily routine of reconstitution, dosing, and tracking takes more time and mental energy than I expected. Overall verdict: AOD-9604 delivered on its primary claims for me, but the magnitude of effects was moderate, not transformative. If your expectations are calibrated for a 15-20 percent improvement in target areas rather than a complete overhaul, you will probably be satisfied.

Comments (4)

Dylan ChaseDEMO·7 months ago

This matches my experience with AOD-9604 almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

5
Jamie CooperDEMO·7 months ago

Appreciate the honest assessment. Too many AOD-9604 reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

2
Scout BarkerDEMO·7 months ago

Question for you: did you get bloodwork done before and during your AOD-9604 protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking AOD-9604 response.

3
Aria FrancoDEMO·7 months ago

I ran AOD-9604 at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

4

Sign in to comment.